CDK4/6 inhibition in low burden and extensive metastatic breast cancer: summary of an ESMO Open—Cancer Horizons pro and con discussion

In December 2017, ESMO Open—Cancer Horizons convened a round-table discussion on the background and latest data regarding cyclin-dependent kinase (CDK)4/6 inhibitors with endocrine therapy (ET) in the treatment of endocrine-sensitive breast cancer (BC). A review on this discussion was published in s...

Descripción completa

Detalles Bibliográficos
Autores principales: Awada, Ahmad, Gligorov, Joseph, Jerusalem, Guy, Preusser, Matthias, Singer, Christian, Zielinski, Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6863664/
https://www.ncbi.nlm.nih.gov/pubmed/31798979
http://dx.doi.org/10.1136/esmoopen-2019-000565

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6863664/
https://www.ncbi.nlm.nih.gov/pubmed/31798979
http://dx.doi.org/10.1136/esmoopen-2019-000565

Ejemplares similares